The study was designed to measure the incidence of dyskinesias
and efficacy as assessed by activities of daily living.
The study is a proof of concept, Phase II clinical trial investigating the use of AVP-923 for the treatment of levodopa induced dyskinesia
(LID) in patients with Parkinson's disease (PD).
The common use of atypical antipsychotics in this age group may lead to various consequences, including movement disorders, such as tardive dyskinesia
However, more dyskinesia
and motor fluctuations are the trade-offs.
are very common, in the majority of patients they do not have a major impact on quality of life and may be improved by adjusting medication.
Targeted symptoms included the following: dyskinesias
(n=13), motor symptomatology (n=15), wearing off (n=2), and freezing (n=3).
If the study shows that Stalevo is superior to traditional levodopa/carbidopa therapy in the time to onset of dyskinesias
, this could change the current treatment paradigm completely," said Professor Werner Poewe, Chair of the Department of Neurology at Innsbruck University, Austria.
While levodopa treatment is the gold standard in terms of potency and effectiveness, it leads to response fluctuations and dyskinesias
, portrayed as abnormal movements usually seen at peak dose (Clarke & Guttman, 2002).
today reported positive results from a clinical study of eltoprazine in levodopa induced dyskinesia
(LID) in Parkinson's disease (PD) patients.
in Parkinson's disease: etiology, impact on quality of life, and treatments.
I started him on an acetylcholinesterase inhibitor, which controlled the tardive dystonia and left the patient free of dyskinesias
This major study in Parkinson's disease (PD) seeks to investigate if, when used as initial therapy, the optimised levodopa medication Stalevo - containing levodopa, carbidopa and entacapone - delays the onset of motor complications, such as dyskinesias
, compared to traditional formulation of levodopa/carbidopa.
were decreased postoperatively in both the stimulator-on and the stimulator-off condition, with 78% and 70% decreases, respectively.
The real advantages favoring pramipexole were in the drug's markedly reduced risks of dyskinesias
and wearing off of medication efficacy, said Dr.
We believe that, by maintaining a steady levodopa blood concentration, ND0601 should minimize or even abolish dyskinesias
and other disabling motor complications associated with long-term oral levodopa administration in advanced Parkinson's disease.